University of Pennsylvania - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
66 Pages - GLDATA58361
$250.00

Summary

University of Pennsylvania (UOP) is an educational university that provides distance learning facilities for professional courses. The university offers courses such as art and archaeology, accounting, biochemistry, bioengineering, biomedical graduate studies, city and regional planning, criminology, fine arts, finance, operations and information management, telecommunications, theatre arts, and visual studies, among others. Its schools include school of arts and sciences, school of dental medicine, school of design, school of engineering and applied science, school of medicine and school of nursing. The university also offers arts, athletics, healthcare, libraries, online learning and global service facilities. UOP is headquartered in Philadelphia, Pennsylvania, the US.

University of Pennsylvania - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
University of Pennsylvania, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
University of Pennsylvania, Medical Devices Deals, 2010 to YTD 2016 12
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
University of Pennsylvania, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Tempus Health Enters into Agreement with Penn Medicine 17
Liquid Biotech Enters into Research Agreement with University of Pennsylvania 18
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 19
Bluepen Biomarkers Enters into Agreement with University of Pennsylvania 20
Biogen Enters into Co-Development Agreement with University of Pennsylvania 21
Seres Therapeutics Enters into Agreement with University of Pennsylvania 23
Audentes Therapeutics Enters into Co-Development with University of Pennsylvania 24
Genisphere Enters into Research Agreement with University of Pennsylvania 25
NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 26
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 27
Janssen Pharma Enters into Agreement with University of Pennsylvania 28
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 29
Epic Sciences Partners with Abramson Cancer Center 30
BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 31
PTC Therapeutics Enters into Agreement with University of Pennsylvania 32
CCFA Enters into Research Agreement with Penn Med and Nestle Health Science 33
Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 34
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 35
PolyMedix Enters Into Co-Development Agreement With University of Pennsylvania 36
Takara Bio Enters Into Research Agreement With University of Pennsylvania 37
Licensing Agreements 38
Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 38
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 39
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 40
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 41
Amyndas Pharma Enters into Licensing Agreement with University of Pennsylvania 43
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania 44
Inovio Pharma Expands Licensing Agreement With University Of Pennsylvania 46
Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 48
Novartis Enters Into Licensing Agreement With University of Pennsylvania For CART-19 49
Eqalix Enters Into Licensing Agreement With Drexel University, University of Pennsylvania And Children's Hospital of Philadelphia 51
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 53
Advaxis Enters Into Licensing Agreement With University of Pennsylvania For ISG15 54
Inovio Pharma Expands Licensing Agreement With University Of Pennsylvania 55
Atrin Pharmaceuticals Enters into Licensing Agreement with University of Pennsylvania 57
Advaxis Amends Its Licensing Agreement With University of Pennsylvania 58
Inovio Biomedical Expands Licensing Agreement With University Of Pennsylvania 59
Equity Offering 60
Tmunity Therapeutics Raises USD10 Million in Equity Financing 60
Asset Transactions 61
University Of Pennsylvania Sells Portion Of Royalty Interest In Juxtapid For US$55 Million 61
Acquisition 62
University of Pennsylvania Health System To Acquire Chester County Hospital 62
University of Pennsylvania - Key Competitors 63
Key Employees 64
Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
University of Pennsylvania, Pharmaceuticals & Healthcare, Key Facts 1
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
University of Pennsylvania, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
University of Pennsylvania, Deals By Therapy Area, 2010 to YTD 2016 10
University of Pennsylvania, Medical Devices Deals, 2010 to YTD 2016 12
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
Tempus Health Enters into Agreement with Penn Medicine 17
Liquid Biotech Enters into Research Agreement with University of Pennsylvania 18
Celgene Enters into Co-Development Agreement with Abramson Cancer Center 19
Bluepen Biomarkers Enters into Agreement with University of Pennsylvania 20
Biogen Enters into Co-Development Agreement with University of Pennsylvania 21
Seres Therapeutics Enters into Agreement with University of Pennsylvania 23
Audentes Therapeutics Enters into Co-Development with University of Pennsylvania 24
Genisphere Enters into Research Agreement with University of Pennsylvania 25
NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 26
Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 27
Janssen Pharma Enters into Agreement with University of Pennsylvania 28
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 29
Epic Sciences Partners with Abramson Cancer Center 30
BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 31
PTC Therapeutics Enters into Agreement with University of Pennsylvania 32
CCFA Enters into Research Agreement with Penn Med and Nestle Health Science 33
Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 34
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 35
PolyMedix Enters Into Co-Development Agreement With University of Pennsylvania 36
Takara Bio Enters Into Research Agreement With University of Pennsylvania 37
Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 38
Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 39
Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 40
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 41
Amyndas Pharma Enters into Licensing Agreement with University of Pennsylvania 43
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania 44
Inovio Pharma Expands Licensing Agreement With University Of Pennsylvania 46
Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 48
Novartis Enters Into Licensing Agreement With University of Pennsylvania For CART-19 49
Eqalix Enters Into Licensing Agreement With Drexel University, University of Pennsylvania And Children's Hospital of Philadelphia 51
ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 53
Advaxis Enters Into Licensing Agreement With University of Pennsylvania For ISG15 54
Inovio Pharma Expands Licensing Agreement With University Of Pennsylvania 55
Atrin Pharmaceuticals Enters into Licensing Agreement with University of Pennsylvania 57
Advaxis Amends Its Licensing Agreement With University of Pennsylvania 58
Inovio Biomedical Expands Licensing Agreement With University Of Pennsylvania 59
Tmunity Therapeutics Raises USD10 Million in Equity Financing 60
University Of Pennsylvania Sells Portion Of Royalty Interest In Juxtapid For US$55 Million 61
University of Pennsylvania Health System To Acquire Chester County Hospital 62
University of Pennsylvania, Key Competitors 63
University of Pennsylvania, Key Employees 64
University of Pennsylvania, Subsidiaries 65

List of Figures
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
University of Pennsylvania, Medical Devices Deals, 2010 to YTD 2016 12

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838